Insulet Corp.
- PODD · Nasdaq
- Surgical & Medical Instruments & Apparatus
- Acton, MA
- 5,400 employees
- CIK 0001145197
Updated from SEC filings through
Top things to know
Executives
-
Ashley McEvoy President and CEO 8-K, 2026-11-04 - Flavia Pease EVP & CFO 4, 2026-02-26
- Flavia H. Pease Chief Financial Officer, Executive Vice President 10-K, 2026-02-18
-
Lisa Blair Davis SVP, Chief HR Officer 4, 2026-08-04 - Michael Panos EVP and CCO 4, 2026-04-02
-
Eric Benjamin EVP and COO 4, 2026-03-03
What leadership is saying
“Our team delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion”
Earnings press release (8-K Ex. 99.1), filed November 4, 2026
Insulet Corp is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Acton, MA. It trades as PODD on Nasdaq. Revenue was $2.7B in the fiscal year ending December 31, 2025, +30.7% from the year before. It reported about 5,400 employees. Ashley McEvoy is President and CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.7B 10-K, 2026-02-18 | $2.1B 10-K, 2026-02-18 | $1.7B 10-K, 2026-02-18 | $1.3B 10-K, 2025-02-21 | $1.1B 10-K, 2024-02-23 |
| Operating income | $474M 10-K, 2026-02-18 | $309M 10-K, 2026-02-18 | $220M 10-K, 2026-02-18 | $37.6M 10-K, 2025-02-21 | $126M 10-K, 2024-02-23 |
| SG&A | $1.2B 10-K, 2026-02-18 | $917M 10-K, 2026-02-18 | $735M 10-K, 2026-02-18 | $588M 10-K, 2025-02-21 | $466M 10-K, 2024-02-23 |
| Net income | $247M 10-K, 2026-02-18 | $418M 10-K, 2026-02-18 | $206M 10-K, 2026-02-18 | $4.6M 10-K, 2025-02-21 | $16.8M 10-K, 2024-02-23 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Ashley McEvoy | President and CEO | 8-K, 2026-11-04 |
| Flavia Pease | EVP & CFO | 4, 2026-02-26 |
| Flavia H. Pease Chief Financial Officer | Chief Financial Officer, Executive Vice President | 10-K, 2026-02-18 |
| Lisa Blair Davis | SVP, Chief HR Officer | 4, 2026-08-04 |
| John Kapples | Named in proxy bio: Senior Vice President and General Counsel | DEF 14A, 2026-04-06 |
| Michael H. Panos | Named in proxy bio: Executive Vice President, Chief Commercial Officer | DEF 14A, 2026-04-06 |
| Michael Panos | EVP and CCO | 4, 2026-04-02 |
| Eric Benjamin Executive Vice President, Chief Operating Officer | EVP and COO | 4, 2026-03-03 |
| Laetitia Cousin Global Regulatory & Quality Medical Device Executive Scaling Global Medtech Orgs | Collaborative Change Agent | FDA/EU MDR/ISO | Board & Executive Reporting | SVP, Reg, Quality & Compliance | 4, 2026-03-03 |
 Prem Singh Senior Vice President, Global Operations | SVP, Global Operations | 4, 2026-03-03 |
| John W. Kapples | SVP and General Counsel | 4, 2026-03-03 |
| Lauren Budden | Group VP, CAO and Controller | 4, 2026-03-03 |
| Jonathan J. Mazelsky | Class II director | 8-K, 2026-06-25 |
| Elizabeth H. Weatherman | Director | 10-K, 2026-02-18 |
| Jessica Hopfield | Director | 10-K, 2026-02-18 |
| Luciana Borio, M.D. | Director | 10-K, 2026-02-18 |
What Insulet Corp does
Insulet Corporation (“we” or the “Company”) is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod ® 5 Automated Insulin Delivery System (“Omnipod 5”), the Omnipod DASH ® Insulin Management System (“Omnipod DASH”), and the Omnipod Insulin Management System (“Classic Omnipod”).
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 69.4 million (as of October 27, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $22.1B (as of June 30, 2025) | 10-K, February 18, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 4, 2026 |
| Latest proxy statement | Meeting May 20, 2026 (filed April 6, 2026) | DEF 14A, April 6, 2026 |
| Auditor | Grant Thornton LLP (Boston, Massachusetts) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 21, 2026 | Ashley McEvoy President and CEO | Buy | 1,100 | $162K | Form 4, August 24, 2026 |
| June 3, 2026 | Timothy C. Stonesifer Director | Buy | 2,790 | $400K | Form 4, June 4, 2026 |
| June 3, 2026 | Luciana Borio Director | Sale | 418 | $60K | Form 4, June 4, 2026 |
| June 3, 2026 | Elizabeth H. Weatherman Director | Buy | 3,450 | $497K | Form 4, June 3, 2026 |
| February 25, 2026 | Michael R. Minogue Director | Buy | 2,030 | $500K | Form 4, February 26, 2026 |
| February 20, 2026 | Ashley McEvoy President and CEO | Buy | 4,300 | $1.0M | Form 4, February 23, 2026 |
| December 15, 2025 | Wayne A.I. Frederick Director | Sale | 1,851 | $543K | Form 4, December 16, 2025 |
| December 5, 2025 | Timothy C. Stonesifer Director | Buy | 962 | $300K | Form 4, December 8, 2025 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-09-21
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-09-16
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-09-10
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-25
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-26
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-21
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-29
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Insulet Corp
- What does Insulet Corp do?
- In its own words, from Item 1 of its 10-K: "Insulet Corporation (“we” or the “Company”) is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod ® 5 Automated Insulin Delivery System (“Omnipod 5”), the Omnipod DASH ® Insulin Management System (“Omnipod DASH”), and the Omnipod Insulin Management System (“Classic Omnipod”)."
- What is Insulet Corp's revenue?
- $2.7B for the fiscal year ending December 31, 2025, from its 10-K filed February 18, 2026.
- Is Insulet Corp profitable?
- Insulet Corp reported net income of $247M for the fiscal year ending December 31, 2025.
- How many employees does Insulet Corp have?
- About 5,400 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Insulet Corp?
- Ashley McEvoy, President and CEO, as named in a 8-K filed November 4, 2026.
- Who is the CFO of Insulet Corp?
- Flavia Pease, EVP & CFO, as named in a 4 filed February 26, 2026.
- Where is Insulet Corp headquartered?
- Acton, MA.
- What is Insulet Corp's stock ticker?
- PODD on Nasdaq.
- What industry is Insulet Corp in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is Insulet Corp's website?
- insulet.com.
- When does Insulet Corp report earnings next?
- February 3, 2027. Source: estimate_8k_pattern.
- Is Insulet Corp a public company?
- Yes. Insulet Corp files with the SEC under CIK 0001145197 and trades as PODD.
- Who audits Insulet Corp?
- Grant Thornton LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of Insulet Corp are outstanding?
- 69.4 million shares as of October 27, 2026, from its 10-Q filed November 4, 2026.
- What is Insulet Corp's public float?
- $22.1B as of June 30, 2025, as reported on the cover of its 10-K filed February 18, 2026.
- How many business segments does Insulet Corp report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 4, 2026.
- When is Insulet Corp's annual shareholder meeting?
- May 20, 2026, per its proxy statement (DEF 14A) filed April 6, 2026.
- Have Insulet Corp insiders traded stock recently?
- Since August 7, 2025, officers and directors reported 6 open-market sales worth about $3.0M and 6 purchases worth about $2.9M on Forms 4 and 5. The most recent: Ashley McEvoy (President and CEO) bought 1,100 shares on August 21, 2026.